DUBAI, UAE / ACCESSWIRE / August 31, 2020 / According to a new market study by Future Market Insights (FMI), the global therapeutic nuclear medicines market will expand at a healthy rate between 2018 and 2028.

The growth of the market is majorly attributed to factors such as the growing acceptance rate of therapeutic nuclear medicines, also known as radiopharmaceuticals, among consumers and medical professionals. These medicines have proven to be largely free of negative side-effects and minimal risk factors.

Furthermore, the rising prevalence of prostate cancer is acting as a major growth attribute to the market. As the per statistics of the U.K. cancer research organization, prostate cancer is the most prevalent cancer among men with over 47,151 cases being diagnosed in 2015. Likewise, the American Cancer Society states that prostate cancer is the most common cause of death in the US.

As the demand for safer, reliable, and less harmful drugs continues to increase in cancer treatment, therapeutic nuclear medicines are finding significant adoption among cancer patients. Along similar lines, continually increasing incidence of bone metastases is also bolstering the growth of the market.

"Owing to the stringent regulations by the US Food and Drugs Administration (FDA), market players are working on complying with the guidelines to receive approvals", opines FMI analyst.

For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Therapeutic Nuclear Medicines Market – Key Takeaways

The global therapeutic nuclear medicines market will expand at an impressive CAGR of 9.7% through the forecast period.
Radium-223 is expected to remain the most prescribed drug by medical professionals, accounting for nearly 78% of the market share in overall market value.
Erbium-169 is forecasted to gain prominence through the forecast period owing to increased usage in the treatment of liver cancer.
Prostate cancer will remain the dominant indication type, accounting for more than 50% of overall market value owing to high incidence.
Bone metastases is expected to remain a lucrative segment while brain tumor and thyroid cancer are forecasted to emerge as significant indication types through the forecast period.

Therapeutic Nuclear Medicines Market – Key Trends

Launch of novel drug formulations has been identified as the major trend in the therapeutic nuclear medicines market.
For instance, the introduction of Xofigo (Radium-223) and Lutathera (Lutetium-177) for the treatment of prostate cancer, neuroblastoma, and synovitis has proven effective and is bestowing lucrative revenue opportunities.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2930

Therapeutic Nuclear Medicines Market – Regional Analysis

North America and Western Europe are forecasted to cumulatively account for nearly 2/3rd of overall market value share.
Emerging economies such as Asia Pacific, Latin America, and Middle East & Africa are anticipated to register higher growth than developed economies, with Asia Pacific forefronting developing economies.
In Asia Pacific, China is expected to register the huge growth owing to the widening cancer patient pool in the country and continual innovations by manufacturers in the region.

Therapeutic Nuclear Medicines Market – Competitive Landscape

Key players operating in the market include some of the key players profiled in the therapeutic nuclear medicines market report include Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc. The competitive landscape represents a highly consolidated structure with the top three players – GE Healthcare, Novartis AG, and Bayer accounting for nearly 87% of market share.

For information on the Research Approach used in the Report, Request Methodology@ https://www.futuremarketinsights.com/askus/rep-gb-2930

Therapeutic Nuclear Medicines Market – Taxonomy

Treatment type:

Radium-223
Iodine-131
Leutitium-177
Yttrium-90
Samarium-153
Strontium-89
Rhenium-188+ Rhenium-186
Erbium-169
Phosphorus-32
Others

Indication:

Prostate cancer
Painful bone metastasis
Thyroid cancer, neuroblastoma
Synovitis
Non-Hodgkins lymphoma
Hepatic metastases
Brain tumor
Others

Distribution channel:

Hospitals
Ambulatory surgical centers
Cancer research institutes

Request a Discount for this Report@ https://www.futuremarketinsights.com/request-discount/rep-gb-2930

Get Valuable Insights into the Therapeutic Nuclear Medicines Market

Future Market Insights, in its new offering, provides an unbiased analysis of the global therapeutic nuclear medicines market, presenting historical demand data and forecast statistics for the period from 2018-2028. The study divulges compelling insights on the therapeutic nuclear medicines market, allowing readers to glean qualitative and quantitative information which will enable them to make informed market decisions in the upcoming forecast period.

Explore Extensive Coverage on FMI's Healthcare, Pharmaceuticals and Medical devices Landscape

Neuroendocrine Carcinoma Treatment Market: FMI's compelling study on the neuroendocrine carcinoma treatment market sheds light on the prominent dynamics influencing the growth trajectory for the upcoming forecast period 2019-2029 through detailed segmental and regional analyses.

Cancer Care Products Market: The cancer care products market report offers a 360-degree analysis, bringing to the fore insights that can help stakeholders identify key challenges and opportunities across the upcoming decade's growth trajectory.

Superficial Radiation Therapy System Market: The global superficial radiation therapy system market is anticipated to surpass an impressive revenue threshold by the end of the forecast period ranging from 2020 to 2030, concludes FMI's recently published research report on the market.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/therapeutic-nuclear-medicines-market
Press Release Source: https://www.futuremarketinsights.com/press-release/therapeutic-nuclear-medicines-market

SOURCE: Future Market Insights

ReleaseID: 604029

NEW YORK, NY / ACCESSWIRE / August 31, 2020 / International Endeavors Corporation "IEC" (OTC PINK:IDVV) today announced that it's soft opening of its eco friendly social distancing glamping resort located in the Temecula Valley Wine Country has been successful, thus paving the way towards further development of the project.

The resort which consists of first class canvas cottages features full bathrooms, showers, and meal preparation areas consists of approximately 6 acres of land. The property is comprised of agricultural land as well as existing commercial structures is in a prime location with easy access to Old Town Temecula and several popular wineries. The resort has started to receive positive reviews online, and because of its size and location guests are able to experience travel during the ongoing pandemic.

Development plans for the property include not only expanding space for Glamping, but also the build out of a themed commercial center featuring a restaurant and retail shops.

More information about the resort, reservations, as well as precautions being taken for travelers during the pandemic can be viewed at www.GlampingTemecula.com

Bill Martin, Vice President of International Endeavors Corporation (IEC) stated "We are proud to announce that we are in the final stages of planning out the build for the remainder of the project. We plan on breaking ground on several aspects of the expansion as soon as September 2020. As this project evolves along with our relationship with Eco-Camps we plan on integrating some of our clean energy holdings in the near future."

This is all possible due to the newly established relationship IDVV developed with Eco-Camps.

Recently International Endeavors Corporation announced its agreement with Eco-camps, an established Glamping company with several destinations operating and signed contracts for the opening of new destinations in California, New York, Idaho and internationally in France and other countries.

According to an article on Fox Business The "glamping" market in the U.S. is projected to reach $4.8 billion in revenue by 2025 at an estimated CAGR rate of 12.5% during that forecast period, and the demand for cabins and safari tents is expected to grow 2.5 times over the next five years. Meanwhile, between 2014 and 2018, growth in U.S. camping households has steadily increased, from 71,500,000 homes in 2014 to nearly 80,000,000 last year. Millennials represent the fastest growing demographic in terms of new campers, with more and more diversity being represented amongst camping demographics.

RELEVANT LINKS

http://www.eco-camps.com

http://www.ecoresortsoftheworld.com

https://www.foxbusiness.com/lifestyle/the-economics-and-phenomena-of-glamping-and-why-its-taking-over-the-travel-industry

About International Endeavors Corporation (OTC:IDVV)

International Endeavors Corporation is engaged in locating and acquiring established companies, brands, and technologies in both the hospitality and green energy sector. The company also has a real estate portfolio that includes commercial property, agricultural land, and buildings.

About Eco Resorts

ECO-CAMPS IS THE LEADING PROVIDER OF OFF-THE-GRID ECO-FRIENDLY SOCIAL DISTANCING ACCOMMODATION

We combine glamorous camping under canvas with the comforts and conveniences of a hotel, delivering unforgettable experiences for our guests in incredible locations.

ECO-CAMPS offers a selection of unique properties around the world by partnering with owners of unique properties to create one of a kind Glamping destinations where other forms of accommodation can't be built.

For more information visit www.Eco-Camps.com

Disclaimer

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Bill Martin, Vice President
Phone: 1-619-343-3199
Email: billmartin@internationalendeavorscorp.com

SOURCE: International Endeavors Corporation, Inc.

ReleaseID: 604048

CRISPR and Cas gene market players are invested in biomedical and life sciences research with demand arising from contract research organizations to bolster revenue streams.

ROCKVILLE, MD / ACCESSWIRE / August 31, 2020 / The CRISPR and Cas genes market is projected to reflect stupendous growth with a 21.2% CAGR between the years 2020 and 2026. A Fact.MR study has found that that the coronavirus outbreak has generated key lucrative opportunities to participants in the market in the short term. Application of CRISPR technologies diagnosing covid-19 cases, and potential for a cure has is likely to contribute to market growth. Wide ranging field of applications will sustain the high growth for years to come.

"CRISPR and Cas gene systems have attracted significant attention among researchers owing to cheaper, faster, and accurate, results in comparison to other existing processes for genome editing. In addition, rising investments in the field by the biotech companies will contribute substantially to the growth of the industry through the forecast period," says the FACT.MR report.

Request a sample of the report to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

CRISPR and Cas Genes Market- Key Takeaways

DNA-free CAS9 products are likely to gain major attention during the forecast period owing to applications in drug development and agriculture genome editing.
Academic research institutes are major contributors to CRISPR and Cas gene developments, supported by growing investments for technology adoption for university projects.
Asia Pacific is a key market for CRISPR & Cas genes market players owing to applications in therapeutics and investments into clinical trials for in vivo applications.

CRISPR and Cas Genes Market- Driving Factors

Widespread use of CRISPR tech in fields of plant genome editing, epigenetics, human germline editing, and therapeutics drive demand.
Investments for low cost drug development and diagnostic initiatives support market prospects.

CRISPR and Cas Genes Market- Major Restraints

Ethical concerns on the use of CRISPR tech to change DNA is a key obstacle to the implementation of CRISPR and Cas genes.
Risk of off-target effects is a key factor hindering market growth prospects.

COVID-19 Impact on CRISPR and Cas Genes Market

CRISPR and CAS gene technology developers are likely to benefit from the coronavirus pandemic. Researchers have been studying these technologies as for potential in covid-19 diagnostic applications. In addition, CRISPR is also providing opportunities in terms of a cure through destroying the RNA structure of the virus. The market is expected to continue growing exponentially even in the post-pandemic era owing to applications in plant gene editing and drug development applications for the foreseeable future.

Explore the global CRISPR and Cas Genes market with 88 figures, 24 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4823/crispr-and-cas-genes-market

Competitive Landscape

Thermo Fisher Scientific, Addgene, and Integrated DNA Technologies are some of the major players in the CRISPR and Cas gene market.

CRISPR and Cas gene researchers have been investing increasingly in tech innovations and diversification of potential applications for a growing number of end use verticals, supporting long term prospects.

For instance, Thermo Fisher Scientific has collaborated with BioEnergy Science Center to use CRISPR/Cas9 protein delivery for a non-GMO process to edit plant genes. Integrated DNA Technologies has engineered a new high-fidelity Cas9 nuclease through unbiased bacterial screen. Beam Therapeutics is collaborating with Addgene for the commercialization of base editing tools for laboratory use in the United States.

About the Report

This study offers readers a comprehensive market forecast of the CRISPR and Cas gene market. Global, regional and country-level analysis of the top industry trends impacting the CRISPR and Cas gene market is covered in this FACT.MR study. The report offers insights on the CRISPR and Cas gene market on the basis of product (Vector-based Cas and DNA-free Cas), application (genome engineering, disease models, functional genomes, knockdown/activation, and others), and end user (biotechnology & pharmaceutical companies, academic research institutes, and contract research organizations) across five regions (North America, Latin America, Europe, Asia Pacific, and MEA).

Explore FACT.MR's Comprehensive Coverage of Healthcare Landscape

Peptide Based Infection Therapeutics Market– Get the latest insights on the peptide-based infection therapeutics market through FACT.MR's report covering analysis for projection period (2017-2022).

Complementary Therapy Devices Market– FACT.MR's study on the complementary therapy devices market covers trends, tech innovations, players, and strategies for 2018-2028.

Hemophilia Gene Therapy Market– Obtain analysis on the hemophilia gene therapy market through FACT.MR's latest report covering competitive analysis, regions, and segment analysis for 2018-2028.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at FACT.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1591/global-crispr-and-cas-genes-market

SOURCE: sales@factmr.com

ReleaseID: 604050

Generated $2.0 million in Revenue, $534,000 in Adjusted EBITDA and a record 83% gross margin

TORONTO, ON / ACCESSWIRE / August 31, 2020 / Adcore Inc. (the "Company" or "Adcore") (TSXV:ADCO)(FSE:ADQ), a leading provider of machine-learning ("ML" and "AI") powered advertising technologies used by digital agencies and advertisers to leverage digital marketing in an effortless and accessible way ("Effortless Advertising"), announced today its financial results for the three and six months ended June 30, 2020.

Second Quarter 2020 Highlights (Unaudited)

Total revenue was $2.0 million compared to $3.6 million for the same period in 2019, a decrease of 45%.

Revenue less media costs (gross margin) was 83% compared to 58% for the same period in 2019, an increase of 43%.

Adjusted EBITDA (see "Use of Non-IFRS Measures") was $534,000 compared to $1.08 million for the same period in 2019, a decrease of 51%.

As of June 30, 2020, total working capital was $6.4 million compared to $5.5 million for the year ended Dec 31, 2019, an increase of $948,000.

As of June 30, 2020, the Company's cash and cash equivalents were $5.6 million, compared to $4.9 million for the year ended Dec 31, 2019, an increase of $755,000.

Continued to invest in its global sales and marketing team and industry-leading technology, including developing Adcore's app for the Shopify app store.

Omri Brill, Chief Executive Officer commented on the results, "As we passed the eye of the storm during April and May 2020 and successfully navigated through a challenging global economic environment, we clearly see a continuous month over month improvement moving forward. Despite an estimated $2.4M impact to our revenues due to COVID-19 during Q2 2020, the Company managed to remain profitable, a clear indication of the strength and robustness of our business model and effectiveness of management's cost saving measures. The $534,000 in Adjusted EBITDA tells this story best.

Mr. Brill continued, "We find ourselves at a historic moment in time as we see a tectonic shift in the way consumers interact and purchase, forcing businesses across all industries to move online and the acceleration of the stay-at-home economy. With its focus on online and eCommerce technology solutions, Adcore is perfectly positioned to take advantage of these dramatic changes. As the Company looks beyond Q2, 2020, we see a strong recovery in the business results for Q3, 2020 and expect this trend to continue and accelerate in Q4, 2020."

Conference Call and Webcast Information

Adcore will host a conference call at 9:00AM ET on September 02, 2020 to answer questions about the financial and operational performance of the Company for the second quarter ended June 30, 2020. The conference call will include a brief statement by management and will focus on answering questions about Adcore's results during the quarter, which can be sent in advance to invest@adcore.com. Please register in advance for this conference call:
https://us02web.zoom.us/j/89356429071

Meeting ID: 893 5642 9071
One tap mobile

+16473744685,,89356429071# Canada
+16475580588,,89356429071# Canada

Dial by your location

+1 929 436 2866 US (New York)
+1 647 374 4685 Canada (Toronto)
+49 69 3807 9883 Germany (Frankfurt)
+972 3 978 6688 Israel (Tel Aviv)
+1 778 907 2071 Canada (Vancouver)
+1 587 328 1099 Canada (Calgary)
+1 669 900 6833 US (San Jose)
+1 312 626 6799 US (Chicago)
+1 346 248 7799 US (Houston)

Meeting ID: 893 5642 9071
Find your local number: https://us02web.zoom.us/u/kdgDa6U5AC

After registering, you will receive a confirmation email containing information about joining the conference call.

USE OF NON-IFRS MEASURES

Adjusted EBITDA

Management uses Adjusted earnings before interest, income taxes, depreciation and amortization ("Adjusted EBITDA") as a key financial metric to evaluate Adcore's operating performance and for planning and forecasting future business operations. Adjusted EBITDA excludes significant items which are non-operating in nature in order to evaluate Adcore's core operating performance against prior periods. Adjusted EBITDA is not a measure of financial performance under GAAP and should be considered in addition to, and not as a substitute for net earnings, overall change in cash or liquidity of the business as a whole. Management believes the use of Adjusted EBITDA allows investors and analysts to understand the results of the continuing operations of the Company and its subsidiary, by excluding certain items that have a disproportionate impact on Adcore's results for a particular period. Management's method of determining non-GAAP financial measures are evaluated periodically and may differ from other companies' methods and therefore may not be comparable to those used by other companies.

The following table presents the adjusted EBITDA for the periods ended:

 
three months ended June 30, 2020
 
 
three months ended June 30, 2019
 

 
CAD$ in thousands (Unaudited)
 

Operating (loss) profit

 
 
264
 
 
 
(1,196)
 

Depreciation and amortization

 
 
128
 
 
 
147
 

Issuance expenses

 
 
–
 
 
 
2,061
 

Share-based payments

 
 
65
 
 
 
74
 

Global Expansion & Relocation Expenses

 
 
77
 
 
 
–
 

Total Adjustments

 
 
270
 
 
 
2,282
 

Adjusted EBITDA

 
 
534
 
 
 
1,086
 

ADCORE's second quarter 2020 financial statements are available on the Company's SEDAR profile at www.sedar.com. All amounts are in CAD and are based on ADCORE's condensed consolidated interim financial statements for the three and six months ended June 30, 2020 and related notes prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Amounts in this press release are in CAD based on the following USD to CAD average exchange rates for each of the relevant periods: For the three months ended June 30, 2020 and 2019, 0.734, and 0.748 respectively.

ABOUT ADCORE

Adcore is a leading provider of machine-learning powered advertising technologies used by digital agencies and advertisers to leverage digital marketing in an effortless and accessible way ("Effortless Advertising") with the goal of scaling activity and maximizing ROI.

By combining extensive industry knowledge and experience with its proprietary artificial intelligence engine, Adcore offers a unique digital marketing solution. In addition to being named numerous times on Deloitte's Fast 50 Technology list, Adcore is a certified Google Premier Partner, Microsoft Partner and TikTok Partner.

Established in 2006, the Company employs over forty people in its headquarters in Tel Aviv, Israel and satellite offices in Melbourne, Australia, Toronto, Canada and Hong Kong, Greater China.

For more information about Adcore, please visit https://www.adcore.com/investors/

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Company. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

For further information please contact:

ADCORE INC.
https://www.adcore.com/investors/

Omri Brill, CEO
Telephone: 647-497-5337
Email: info@adcore.com

Martijn van den Bemd, GM North America
Telephone: 647-497-5337
Email: martijn@adcore.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or the accuracy of this release.

SOURCE: Adcore Inc.

ReleaseID: 604049

According to Dr. Alina Sholar, Skin Science Soul is the first plastic surgery and medical aesthetic office in Austin to offer several modern procedures

AUSTIN, TX / ACCESSWIRE / August 31, 2020 / Dr. Alina Sholar is proud to be the first plastic surgeon in Austin to offer Tetra CoolPeel, VirtueRF and Stem Cell Facelift procedures at her practice, Skin Science Soul.

Dr. Alina Sholar is a plastic surgeon and serial entrepreneur, owning three businesses: Skin Science Soul, Serenity Medical Centers, and Sage Practice Solutions.

Tetra CoolPeel is a non-invasive laser treatment procedure used to treat wrinkles, signs of aging, skin texture, and other skin imperfections. The procedure is completed through unique pulse control, delivering a fractional ablative treatment that causes no thermal damage to surrounding tissues. This maximizes results while minimizing downtime. In the past, this level of skin resurfacing was only accomplished with more painful, less precise laser procedures.

Over the past 5 years, RF Microneedling has grown to be one of the most in-demand and profitable treatments in aesthetics. The VirtueRF represents a best-in-class technology that utilizes a precise Robotic Precision Delivery system of microneedling combined with radiofrequency energy that brings comfort, unmatched results od collagen induction and kin tightening, and with no downtime.

A stem cell facelift procedure uses the regenerative power of patients' own stem cells to potentially provide a more youthful appearance in complexion. Dr. Sholar notes that regenerative cell therapies are simpler and less invasive than surgical procedures.

"While stem cell therapy often provides significant skin regeneration results, and when applied for aesthetic purposes enhances and the maximizes the results for other procedures like the CoolPeel and VIrtueRF. Basically, you have more youthful cells to work with to create new collagen and elastin to make more youthful skin," note experts from Skin Science Soul.

"We are happy to be the first facility in Austin, Texas to be able to offer these services for our patients," says Dr. Alina Sholar.

"We are firm in our commitment to provide the latest innovations in aesthetic medicine."

For more information, please visit https://www.skinsciencesoul.com/.

About Dr. Alina Sholar

Throughout her illustrious career, Dr. Alina Sholar has made a name for herself as a respected plastic surgeon, female entrepreneur, and mentor. She attended Texas A&M University on a full-tuition merit scholarship and earned a B.S. degree in Biomedical Science with Magna Cum Laude honors in 1994. In 1999, she earned her MD degree from the University of Texas Medical Branch, where she was also awarded the prestigious Janet M. Glasgow Memorial Award and Achievement Citation for Women in Medicine. She then completed a full five-year residency in General Surgery at the University of Louisville, where she was awarded Best Resident Instructor and Mentor by the students of the University of Louisville School of Medicine. She also completed an additional residency in Plastic and Reconstructive Surgery at the University of Tennessee, serving as Chief Resident in 2006. She received multiple awards and publications in research areas such as the efficacy of treatment at Tertiary Care Wound Centers and the advanced reconstructive techniques required after major facial trauma and infections. She was certified by the American Board of Plastic Surgery in 2008. Dr. Sholar currently owns Skin Science Soul by Dr. Sholar, her plastic surgery and medical aesthetic practice. She is also the owner and CEO of Serenity Medical Centers and Sage Practice Solutions. Dr. Sholar also provides pro bono business consulting for women entrepreneurs in need. Further, she mentors young female physicians and non-physician entrepreneurs. Dr. Sholar is also a philanthropist and regularly gives back to her local communities, supporting women-owned businesses and organizations that benefit women and children.

Contact:

Dr. Alina Sholar
drsholar@medcenters.org
https://www.linkedin.com/in/dr-alina-sholar-md-379b0422/

SOURCE: Dr. Alina Sholar

ReleaseID: 604047

– Variable Gross Margin of 23% at Q2 2020 is up approximately 90% from Q1 2020 as Company benefits from higher margin revenue

SANTA ROSA, CA / ACCESSWIRE / August 31, 2020 / GABY Inc. ("GABY" or the "Company") (CSE:GABY) (OTCQB:GABLF), a California-focused, Cannabis and CBD consumer goods and distribution company, is pleased to provide its second quarter 2020 results (ended June 30, 2020).

Q2 2020 Financial Highlights

Revenue was $.7 million compared to $2.1 million during the same quarter in 2019
Adjusted EBTIDA from Continuing Operationsi was (1.6 million) i compared to ($3.5 million) i during the same quarter last year. The improvement of $1.9 million was primarily due to a decrease in SG&A expenses of $2.0 million.
Variable Gross Margin improved to 23% compared to 11% during the same quarter in 2019 and negative 1.0% in Q1 2020

The improved Adjusted EBITDA from continuing operations[i] and significantly improved Variable Gross Margin in the quarter reflects a number of initiatives that GABY has implemented early in 2020 and continued into Q2 2020, as follows:

Relocating all operating and finance roles to Santa Rosa, California, after the positions of the President and COO, and the CFO and all operating and supporting staff in Canada were terminated;
Consolidation of its office and operations to Santa Rosa, California eliminating five out of six office and warehouse leases;
Founder, Margot Micallef, adding to her role of CEO, the day to day responsibility of running the operations after terminating the employment of the President and Chief Operating Officer and other senior sales and operating roles;

Shuttering its cultivation and manufacturing operations, removing the capital investment required to develop upstream operations;
Broadening its procurement infrastructure to several third-party contractors having cultivation relationships with a wider base of farmers in lieu of an in-house procurement department with more limited cultivation relationships;
Simplifying its operations, by creating greater efficiencies, rationalizing staff count and lowering costs;
Developing more effective standard operational protocols to maximize efficient regulatory compliance and simplify operating processes;
Shuttering unprofitable business operations, including its frozen food operations, Gabriella's Kitchen or GK which resulted in $0.7 Million of savings in both periods as reflected in the loss from discontinued operations;

Terminating third party service and distribution relationships that were providing insufficient or low margins and replacing them with higher margin relationships.

The Company anticipates that through management's cost cutting initiatives GABY will save approximately $6MM on an annualized basis.

In addition, GABY replaced a number of senior positions with people experienced in start-ups who know how to do a lot with a little, having the discipline to push its revenue mix towards slower growing but more sustainable higher margin revenue.

"We entered Q2 with the uncertainty created by COVID-19. This reality impacted our revenue in three ways: It resulted in lower productivity and increased production costs, given the need to quarantine and social distance (we split our production crew into three teams instead of one producing fewer units per day than customary); It challenged our sales department and demand from our dispensaries (who were uncertain as to the impact of COVID-19 and how they would structure themselves to serve customers); and it made enforcement of the illicit market more challenging for regulatory bodies who were closed during the first few months following the start of the pandemic in California or who temporarily furloughed employees. This temporary lack of enforcement emboldened the illicit market and heightened their activity raising prices for available raw materials to the point that it was not economic for us to purchase raw materials for resale, explained Margot Micallef, Founder, President and Chief Executive Officer of GABY.

"It takes discipline to resist the temptation to build inventory when prices temporarily spike and courage to watch inventory levels become depleted as a result. But it is this discipline and this courage which builds companies in the long term. We entered 2020 with the promise that we would not sacrifice margin for revenue. And we have stuck to that promise" Ms. Micallef stated.

"While we would have liked Q2 revenue to have been higher, the cost cutting, operational restructuring, and risk mitigation strategies we implemented and the discipline we exhibited especially in Q2 2020 enabled us to significantly increase variable gross margin to 23%", Ms. Micallef added.

She concluded: "All these changes have positioned us to meet our goal to be profitable by year end. Our focus for the remainder of the year is to pursue sustainable growth both organically and by acquisition".

GABY's shares trade on the Canadian Securities Exchange ("CSE") under the symbol "GABY" and on the OTCQB under the symbol "GABLF". For more information, visit www.GABYinc.com.

For further inquiries, please contact:

Margot Micallef, Founder & CEO at Margot@GABYinc.com or Investor Relations at IR@GABYinc.com or 800-674-2239.

(i) NOTE- NON-GAAP MEAUSRES

Adjusted EBITDA from Continuing Operations

Adjusted EBITDA from Continuing Operations in respect of the comparative periods of Q2-20 below does not have any standardized meaning as prescribed by IFRS, and, therefore, is considered a non-GAAP measure and may not be comparable to similar measures presented by other issuers. The non-GAAP measure of Adjusted EBITDA from continuing operations, combined with IFRS measures, such as revenue and net loss, is a useful measure to our investors as management relies on it to provide a measure of operating cash flows before servicing debt, income taxes, capital expenditures and other gains and losses.

Adjusted EBITDA from Continuing Operations for the periods ended below are calculated as follows:

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Sonoma Pacific Distribution, Inc., is a subsidiary of GABY. Sonoma Pacific holds a type 11 cannabis license in the State of California. Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), readers are cautioned that in the United States ("U.S."), cannabis is largely regulated at the State level. Cannabis is legal in the State of California. However, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the business operated by Sonoma Pacific is conducted in a manner consistent with the State law of California, as applicable, and it is in compliance with regulatory and licensing requirements applicable in the State of California. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought either GABY or its subsidiary. Any such proceedings brought against GABY or its subsidiary may materially adversely affect the Company's operations and financial performance generally and in the U.S. market specifically.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: GABY Inc.

ReleaseID: 604028

VICTORIA, BC / ACCESSWIRE / August 31, 2020 / Erin Ventures Inc. (TSXV:EV) reports that it has filed its compulsory Annual Work Report and License Extension Application for its Piskanja Boron Project, as required by the Serbian Law on Mining and Geological Exploration. In accordance with these regulations, Erin has notified the Mining Ministry of its intention to proceed with the "Certification of Reserves" process, which consists primarily of the submission of a Serbian compliant Mineral Resource Calculation and Technical Economic Assessment. The law affords Erin up to 3 years (from the date of the license extension approval) on this license phase, and requires Erin to complete the necessary studies and gain approval for the "Certification of Reserves" as well as the "Approval of the Exploitation Field", as the first two (of three) steps in the mine licensing process.

Piskanja is Erin's wholly owned boron deposit with an indicated mineral resource of 7.8 million tonnes (averaging 31.0 per cent B2O3), and an inferred resource of 3.4 million tonnes (averaging 28.6 per cent B2O3), calculated in accordance with the Canadian Institute of Mining Definition Standards on Mineral Resources and Reserves (CIM Standards), as disclosed in Erin's report titled, "Mineral Resource Estimate Update On The Piskanja Borate Project, Serbia, October 2016 – Amended February 28 2019" – prepared by SRK Consulting (UK) Ltd. The responsible persons for the updated MRE are Dr Mike Armitage (C.Eng. C.Geol.) and Dr Mikhail Tsypukov who are both full time employees of SRK and Qualified Persons in accordance with the CIM Definition Standards on Mineral Resources and Reserves (CIM Standards) and independent of Erin Ventures.

On behalf of the Board of Directors,

Blake Fallis, General Manager

About Erin Ventures

Erin Ventures Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin's shares are traded on the TSX Venture Exchange under the symbol "EV". For detailed information please see Erin's website at www.erinventures.com or the Company's filed documents at www.sedar.com.

For further information, please contact: 

Erin Ventures Inc. 
Blake Fallis, General Manager 
Phone: 1-250- 384-1999 or 1-888-289-3746
info@erinventures.com 
www.erinventures.com 

Erin's Public Quotations

Canada
TSX Venture: EV

USA
SEC12G3-2(B)#82-4432

Europe
Berlin: EKV

The technical information in this release was prepared and approved by James E Wallis, M.Sc. (Eng), P. Eng., a director of the company, who is a Qualified Person under National Instrument 43-101.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

Certain statements in this news release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning anticipated approvals; and results of the completion of the transactions contemplated in this news release. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "should", "plans" or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, the risks that: (1) the license is not renewed; and, (2) Erin may not achieve the results currently anticipated. Although Erin believes that the expectations reflected in its forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because Erin can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this news release, assumptions have been made regarding and are implicit in, among other things, the timely receipt of required regulatory approvals. Details of the risk factors relating to Erin and its business are discussed under the heading "Risks and Uncertainties" in Erin's most recent regulatory filings which are posted on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Erin and described in the forward looking information. The forward-looking information contained in this news release is made as of the date hereof and Erin undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Mineral resources are not mineral reserves and do not have demonstrated economic viability. "Inferred Resources" have a great amount of uncertainty as to their existence, and economic and legal feasibility. Investors are cautioned not to assume that all or any part of an inferred mineral resource reported in this news release will ever be upgraded to a higher category or to reserves. U.S. persons are advised that while mineral resources are recognized under Canadian regulations, the U.S. Securities and Exchange Commission does not recognize them. U.S. persons are also cautioned not to assume that all or any part of an inferred mineral resource is economically or legally mineable.

SOURCE: Erin Ventures Inc.

ReleaseID: 603880

SHANGHAI, CHINA / ACCESSWIRE / August 31, 2020 / Though 5G will dominate the market in the next decade, the technology transition will take 10 years, Counterpoint points out. Over the next five years, we estimate 5G subscription uptake will be significantly faster than LTE when it was introduced. However, 4G and 5G technologies will coexist for a long time to come. During the transition period, countries will phase out 2G and 3G, and 4G will play an important role, especially in India, Middle East/Africa, Latin America and other parts of Asia-Pacific. India, the Middle East and Africa remain the main drivers of the feature phone market, with more than 740 million units shipped in the next five years, or accounting for about 75% of global feature phone shipments.

While users at the bottom of the social pyramid will still be buying feature phones, more and more feature phones are starting to support advanced 4G networks, with improvements in performance, specs, and screen sizes. These enhanced feature phones can meet the diverse needs of users. Some users will choose to buy and use feature phones even if they can afford a smart phone.

Indeed, shipments of 4G feature phones are growing across regions, as Reliance's Jio Phone in India shows. In the future, 4G mobile phones will also bring considerable sales volume and income to the ecological participants. By 2024, India will be the world's largest market for feature phones, followed by Bangladesh and Nigeria. The revival of Nokia's feature phones, the steady growth of brands such as Itel and Tecno in Africa, and sales of more powerful feature phones such as Jio Phone in India have provided continued momentum for the feature Phone market. True Superhero 4G and other multifunctional 4G feature phones based on customized operating systems are emerging and encourage upstream component manufacturers to release solutions to get a profit from this market. For example, UNISOC launched T117 for 4G feature phones, and thus took the lead in the major feature phone market.

Components are also a key part of driving market growth, with primary chip solution providers playing a vital role, such as providing new solutions with affordable prices and superior performance, the report said. During the 2019 Mobile Congress in India, UNISOC unveiled the highly integrated T117 main chip platform in response to the growing demand for 4G feature phones in the mass market. The T117 integrates LTE/WCDMA/GSM modems, BT/FM, and multimedia capabilities with built-in LPDDR to minimize board area. The chip also supports HD voice, VoLTE and LTE dual cards and dual standby, greatly improving the phone's calling experience. T117 series achieves a balance between cost, performance and power consumption and is the ideal 4G smart phone platform for basic Internet users with limited budgets.

The success of phones such as the JioPhone in India has reignited the attention of the market, as manufacturers explore potential market opportunities to upgrade from basic phones to enhanced 4G phones. In 2019, in the Middle East, Africa and India, With moderate price and excellent performance, UNISOC accounted for more than 60% and 50% respectively in the base band market of feature phones, occupying the first position in the market.

In addition, according to Counterpoint's report, operators will face significant market opportunities in the 4G mobile phone market.4G feature phones could generate $7 billion in revenue for operators. Details refer to: Counterpoint website – free English version and Chinese version download link

https://www.counterpointresearch.com/cellular-technology-transitions-potential-soc-players/

Media Contact:
UNISOC Technologies Co., Ltd
Miranda Wu – UNISOC PR Team
E-mail: mengran.wu@unisoc.com
Website: http://www.unisoc.com

SOURCE: UNISOC Technologies Co., Ltd

ReleaseID: 604045

MEMS sensor manufacturers are displaying interest in sensor fusion technologies with low cost, miniaturization, and integration for research applications.

ROCKVILLE, MD / ACCESSWIRE / August 31, 2020 / The MEMS sensors market is estimated to rise at an exponential 18% CAGR between assessment years from 2020 to 2027. The ongoing coronavirus outbreak has restricted demand for MEMS sensors in the short-term. Suspension or restricted activity in the automotive and consumer goods sector during the crisis has hurt demand. On the other hand, potential for MEMS sensors in healthcare and covid-19 diagnosis applications will provide niche growth opportunities.

"MEMS sensors are compatible to on-chip integration. Furthermore, these sensors can also be manufactured at a mass scale, at low cost while maintaining performance and reliability standards. These factors will remain crucial in growth of the industry through the projection period," says the Fact.MR analyst.

Request a report sample to gain more market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4528

MEMS Sensors Market – Important Takeaways

Collision avoidance applications in automotive platforms contribute significantly to revenue with ADAS systems going mainstream.
Optical MEMS sensors account for a large market share on the back of growing applications in consumer goods sector.
Asia Pacific is a major market for MEMS sensors with presence of leading market players in China and India.

MEMS Sensors Market – Driving Factors

Asset tracking and smart grid applications in industrial automation provides impetus to market growth.
Niche applications of MEMS sensors in biomedicine are providing major growth opportunities.

MEMS Sensors Market – Leading Constraints

Calibration and accuracy problems remain a major challenge for MEMS sensor manufacturers.
High levels of competition in the industry reduce profit margins and restrict market players.

Anticipated Market Impact by Coronavirus Outbreak

The impact of the coronavirus pandemic on the MEMS sensors market has largely been negative. Suspension of industrial activities including the automotive, manufacturing, and consumer goods sector has limited the demand for MEMS sensors in the short term. On the other hand, potential applications in covid-19 virus detection for PCR analysis machines are generating lucrative growth opportunities, which will help in a faster recovery of the industry, and lower losses during the crisis.

Explore the global MEMS sensor market with 103 figures, 131 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4528/mems-sensor-market

Competition Landscape

Some of the leading manufacturers in the global MEMS sensor market include but are not limited to Panasonic Corporation, Infineon Technologies, Texas Instruments, Global Foundries, SilTerra Malaysia Sdn. Bhd., and ST Microelectronics N.V.

Players in the MEMS sensor market have been increasingly pushing for development and launch of new products in line with expanding the scope of applications in multiple end use verticals.

For example, Bosch has unveiled its new SMI230 MEMS sensor for automotive navigation platforms, complementing conventional GPS systems. Posifa Technologies has introduced the PAV3000 air velocity MEMS sensors for superior resistance to pressure and clogging. Similarly, InvenSense has introduced ICM-42688-P MEMS sensor for motion tracking applications.

More on the Report

The FACT.MR's market research report provides in-depth insights on MEMS sensor market. The market is scrutinized according to type (mechanical, optical, thermal, chemical & biological, and others), fabrication material (silicon, polymer, ceramics, and metal), and application (automotive, consumer, medical, industrial, and others) across five key regions (North America, Latin America, Europe, Asia Pacific, and Middle East and Africa).

Explore Wide-ranging Coverage of FACT.MR's ICT Landscape

MEMS Gyroscopes Market: Find insights on the global MEMS Gyroscopes market with analysis of segments, statistics, influencers, market players and business strategies adopted over a 10-year forecast period.

Current Sensor Market: FACT.MR's report on the Current Sensor market offers insights on the market set for strong growth during 2020-2030, including restraining forces, revenue sources, market leaders, and market strategies.

Pressure Sensor Market: Read an analysis on the Pressure Sensor market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the ICT industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest market reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1592/mems-sensor-market-trends

SOURCE: Fact.MR

ReleaseID: 604046

GIBRALTAR / ACCESSWIRE / August 31, 2020 / IOV Labs has integrated Chainlink's decentralized oracles into the RSK and RIF ecosystems. This allows RSK developers to access critical price feeds and data resources generated outside the blockchain and use them as inputs to trigger RSK's Bitcoin-based smart contracts.

RSK and RIF's technical teams are working hard to integrate Chainlink's protocol at the infrastructure level to ensure developers can use Chainlink oracles without any external dependencies on other blockchains. The integration is already live on testnet and was completed in only a few weeks due to the high modularity of the Chainlink protocol.

As the market-leading oracle protocol, Chainlink's technology is utilized by many leading smart contract development teams and large enterprises within the blockchain and tech space. It powers the majority of blockchain platforms and DeFi applications that are reliant on oracles to connect with accurate off-chain data, delivered trustlessly in near real-time.

"Chainlink is as synonymous with oracles as RSK is with Bitcoin smart contracts," said Julian Rodriguez, Head of RIF Gateways. "By combining the two, developers can capitalize on a smart contract network that's anchored to the strongest Proof of Work blockchain, and connected to the best decentralized oracle solution on the market. The synergies between Chainlink and IOV Labs are extensive, and we look forward to exploring ways to enhance the utility of RSK and RIF by building upon Chainlink's best-in-class oracle service."

RIF Gateways, one of the core components of RIF, aims to provide a simplified and unified experience for developers to access any oracle or data service that brings information into the blockchain from the external world. Thus, the integration will use RIF Gateways to make Chainlink oracle network easily accessible to RSK developers.

The integration also extends the capabilities of Chainlink, opening its network of node operators to the most valuable and decentralized blockchain in the world – Bitcoin, which anchors RSK. The integration further demonstrates the feasibility of implementing technology protocols that can spawn across multiple blockchains, building bridges between existing platforms and teams.

Daniel Kochis, Head of Chainlink Business Development, commented on the integration, stating: "The blockchain space has long wanted to build smart contracts anchored to the security of the Bitcoin blockchain. We're excited to collaborate with the IOV Labs team making that a reality by providing RSK with secure and reliable oracles to empower more useful smart contract applications that fully integrate with widely used data resources and systems."

Developers can view the GitHub here: https://github.com/smartcontractkit/chainlink-RSK

About IOVlabs

IOVlabs develops the blockchain technologies needed for a new global financial ecosystem; one that fosters opportunity, transparency, and trust. The organization currently develops the RSK Smart Contract Network, RSK Infrastructure Framework (RIF) , and Taringa! Platforms.

The RSK Network is one of the more secure smart contract platforms in the world, designed to leverage Bitcoin's unparalleled hash power while extending its capabilities. RSK Infrastructure Framework (RIF) is a suite of open and decentralized infrastructure protocols that enable faster, easier and scalable development of distributed applications (dApps) within a unified environment. Taringa is Latin America's largest Spanish speaking social network with 30 million users and 1,000 active online communities.

About Chainlink

Chainlink is a decentralized oracle network that helps resolve connectivity issues with smart contracts, enabling users to build blockchain-based smart contracts that securely access off-chain data feeds, web APIs, and traditional bank payments. By doing so, Chainlink transforms the role that smart contracts can play in a vast number of sectors, including financial services, insurance, and supply chain. Chainlink provides highly secure and reliable oracles to large enterprises (Google, Oracle, and SWIFT) and leading smart contract development teams such as Polkadot/Substrate, Synthetix, Loopring, Aave, OpenLaw, Conflux, and many others.

Learn more by visiting the Chainlink website.

Contact:

Dan Edelstein
pr@marketacross.com

SOURCE: IOV Labs

ReleaseID: 604037